Get in Touch
Who we are
Who we are

Rapid Innovate ModelTM

InfinixBio is a full-service, cost-effective CRO that partners with our clients to expand their capabilities and meet key milestones. Our cross-functional interdisciplinary team comprises expert scientists operating in multiple BSL Level II labs. Our team is comprised of 38% PhDs and collectively has over 60 issued and pending patents.

Learn more

Our Services

Early Drug Development

Assay Development and Sample Testing

Assay
Development

Protein
Biochemistry

Genetic
Engineering​

Cell Line Development and Cell Biology

Target Identification and Validation

Hit
Identification

Hit-to-Lead
Development Support

Pre-Clinical (GLP and non-GLP)

Assay Development, Validation,
and Sample Testing

Clinical (GLP)

Assay Development, Validation,
and Sample Testing

Pharmacokinetic
(PK) Analysis

Immunogenicity Testing (ADA Analysis)​

Gene Therapy Immunogenicity​

Biomarker Testing Services

First In-Human
Dosing

Phase 1 & 2 Clinical Testing Support

Our Clients

Our team works with virtual and mid-size biotech, industry consulting firms, and pharmaceutical companies to accelerate technological progress through a fully collaborative development process. We are a contract-based business and do not require an equity position or IP ownership.

Schedule a Consultation

See what our
customers have to say

"We came to InfinixBio with a challenge to increase the yield in our manufacturing process of an expensive and complex compound. InfinixBio scientists designed and performed meticulous R&D experiments with effective communication throughout the project. The results led to a ten-fold increase in lab scale product and a 400% improvement in the manufacturing yield."

Vice President, Bexion
Sandra Nelson, PhD

"InfinixBio has developed and validated multiple complex assays (including ADA and Potency) for our novel therapeutic. Their animal model selection saved us time and money. With the help of their molecular biology expertise, and GLP compliance, we are preparing for an IND submission."

Chief Technology Officer, Sonnet
Susan Dexter

"We are entering our 10th year working with InfinixBio. They have been crucial in providing expert genetic engineering and cell biology expertise in assisting us expand our product line development of therapeutic compounds."

Principal Scientist, Protein Biochemistry, Sutro
Dan Groff, PhD

Mutual growth is the result of strategic partnerships

Get in Touch